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BCL-USummary Follicular lymphoma (FL) in situ (FLIS) was first described and proposed as a distinct entity
associated with an indolent clinical course in 2002. To gain further insight into the biology of this enigmatic
lymphoproliferation, we analyzed morphologic, phenotypic, cytogenetic and molecular features of tissue
specimens manifesting a pattern of follicular colonization by Bcl-2bright+CD10+ B-cells and associated
lymphomas from 13 adults and evaluated their clinical outcomes. We observed this immunoarchitectural
pattern in lymph nodes (n = 8), at extranodal sites (n = 4), or at both locations (n = 1) at diagnosis. All
except 3 cases showed concomitant bright CD10 expression. Six (46%) patients had synchronous and 2
(15%) developed metachronous B-cell lymphomas, with 5 representing high-grade lymphomas. The
Bcl-2bright+CD10+ B-cells colonizing reactive follicles and synchronous lymphomas were clonally related in
4/5 (80%) cases analyzed and 5/6 (83%) displayed BCL2 translocations. Two cases exhibited complex
karyotypes in both components; a genetic “triple hit” was detected in one instance and 2 copies of
t(14,18) were observed in a lymph node biopsy lacking evidence of lymphoma from an individual with
stage 4 disease, suspected on imaging, who subsequently displayed a mantle zone/perifollicular infiltrate
of Bcl-2bright+CD10+ B-cells in the adenoids. Our findings suggest that bright Bcl-2, and often bright CD10
expression, by B-cells colonizing reactive follicles might represent a phenomenon related to follicular
homing of lymphoma, rather than being an attribute of preneoplastic FL precursors. Furthermore, due to the
relatively high frequency of overt lymphomas observed, complete staging workup is recommended for
patients exhibiting a Bcl-2bright+CD10+ B-cell follicular colonization pattern on biopsy.
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Follicular lymphoma (FL) is genetically characterized by
the translocation t(14;18)(q32;q21) in the majority of
cases [1], with low-grade FLs displaying a higher frequency
of this abnormality [2]. The t(14;18)(q32;q21) is thought to
arise in bone marrow B-cell precursors due to aberrant VDJ
recombination leading to deregulated BCL2 expression [3].
However, cells harboring only this translocation have limited
neoplastic potential.
Folliculotropism, with preferential colonization of germi-
nal centers (GCs) is a unique characteristic of FL, rarely seen
in other types of lymphomas. However, other patterns of
lymphoid tissue infiltration by FL, eg, interfollicular and
diffuse have been described, which can be associated with
distinct immunophenotypic features of the neoplastic cells,
disease grade and underlying cytogenetic aberrations [1,4].
Moreover, lymph node involvement by FL may be subtle at
times, only involving a small portion of the lymph node or a
few follicles. In 2002, a novel morphologic and phenotypic
pattern of FL was identified, characterized by architecturally
intact lymph nodes displaying follicular colonization by Bcl-
2bright+CD10+ B-cells, referred to as “in-situ localization of
follicular lymphoma” or “follicular lymphoma in-situ”
(FLIS) [5]. In 40% to 60% of these cases, no evidence of
concomitant overt lymphoma was discerned, either at
presentation and/or on follow-up [5]. Hence, FLIS was
suggested to represent an early stage in FL pathogenesis,
associated with indolent clinical behavior [5]. Since the
original publication, a few case reports and case series
describing this entity and its associated clinical manifesta-
tions have been published [6–12].
The aim of our study was to gain further insight into
the biologic and clinical significance of the immunoarchi-
tectural pattern referred to as FLIS that we define as the
“Bcl-2bright+CD10+ B-cell follicular colonization pattern”
diagnosed at our institution over the past 10 years. We
determined the presence and type of concurrent or
subsequent lymphomas occurring in individuals exhibiting
this pattern and assessed the cytogenetic, molecular and
clinical characteristics of such cases.2. Materials and methods
2.1. Case selection
We retrospectively searched our departmental database of
FL cases from January 2002 to June 2012 to identify biopsies
or surgical resection specimens of lymph nodes or extranodal
tissue that were coded to document the presence of reactive
follicles colonized by Bcl-2bright+CD10+ B-cells, as de-
scribed by Cong et al [5]. Data regarding patient de-
mographics, type of associated or subsequent lymphoma,
results of imaging studies, therapeutic regimens and clinicaloutcomes were obtained from our laboratory and clinical
information systems. This study was approved by our
institutional review board.
2.2. Morphology and immunohistochemistry
Morphologic features were evaluated by reviewing
hematoxylin and eosin (H&E)–stained sections of formalin-
fixed, paraffin-embedded (FFPE) tissue. Immunohistochem-
ical staining was performed using a panel of antibodies.
Staining for CD20 (clone MJ1), CD3 (clone LN10), Bcl-6
(clone LN22), Bcl-2 (clone BCL-2/100/D) (all Novocastra,
Buffalo Grove, Illinois), MUM1 (clone MUM1p) (Dako,
Carpinteria, CA), LMO2 (clone SP51), OCT2 (clone MRQ-
2), and BOB1 (clone SP92) (all Cell Marque, Rocklin, CA)
was performed after antigen retrieval at pH 9.0 for 20 min,
using the Leica Bond III autostainer (Leica, Wetzlar,
Germany). Staining for CD10 (clone SP67), CD21 (clone
EP3093), and Ki-67 (clone 30–9) (all Ventana Medical
Systems, Tucson, AZ) was performed after antigen retrieval at
pH 8.3 for 30 minutes, using the Ventana Ultra platform
(Ventana Medical Systems, Tucson, AZ). The Bond Polymer
Refine Detection (Leica) or the Ultra View Universal DAB
Detection Kit (Ventana) was used for visualization, with
diaminobenzidine as the chromogen.
2.3. Cytogenetic analysis
G-band karyotype analysis was performed on metaphase
preparations after unstimulated overnight cultures, and
karyotypes were described according to the International
System for Human Cytogenetic Nomenclature [13].
Fluorescence in situ hybridization (FISH) analysis was
performed on metaphase spreads and/or FFPE sections using
IGH/BCL2 dual color fusion and/or BCL2 break-apart
probes (Abbott Molecular, Des Plaines, IL), per standard
protocols. FISH analysis for BCL6, and MYC (Abbott
Molecular) was performed as applicable. Fluorescence
signals were analyzed using the Cytovision Imaging system
attached to a Nikon Eclipse 600 microscope (Applied
Imaging, Santa Clara, CA), and 200–500 cells were scored
for each hybridization. To evaluate tissue localization of
FISH signals, FFPE sections from 9 cases containing only
reactive follicles manifesting the Bcl-2bright+CD10+ B-cell
colonization pattern were selected, and coordinates of
abnormal follicles targeted for FISH signal detection were
marked on the underside of the slides after reviewing
corresponding serial H&E stained sections.
2.4. Immunoglobulin heavy chain gene
rearrangement analysis
Polymerase chain reaction (PCR) to ascertain clonal
immunoglobulin heavy chain gene (IGH) rearrangements
was performed on DNA extracted from fresh or FFPE tissue
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high resolution capillary electrophoresis using a 3130
Genetic Analyzer (Applied Biosystems, Foster City, CA).3. Results
3.1. Case characteristics
Of the 302 patients diagnosed with FL at our institution
during the study interval (208 lymph nodes, 94 extranodal
sites), we encountered 13 patients that exhibited a distinct
pattern of follicular colonization byBcl-2bright+CD10+ B-cells.
This pattern was detected at presentation in lymph nodes (n =
8), at extranodal sites (n = 4) or involving both (n = 1)
(Table 1); representing 9/208 (4.3%) of nodal and 5/94 (5.3%)
of extranodal cases. Extranodal sites at initial presentation
included thyroid (n = 1), duodenum (n = 1), jejunum (n = 1),
ileum (n = 1), and subcutaneous tissue (n = 1); one patient
developed a recurrent lesion in the adenoids.
Follicular colonization by Bcl-2bright+CD10+ B-cells in
lymph nodes was observed as an isolated finding at
presentation in 5 patients (cases 1–5, Table 1); synchronous
lymphomas were diagnosed in 6 patients (cases 6–11,
Table 1), comprising low-grade FL (n = 2), diffuse large B-
cell lymphoma (DLBCL) (n = 2) and “B-cell lymphoma,
unclassifiable (BCL-U), with features intermediate between
DLBCL and Burkitt lymphoma” (n = 2). Metachronous
lymphomas were documented in 2 patients (cases 12 and 13,
Table 1), including low-grade FL (n = 2) and DLBCL (n = 1).
3.2. Morphology and phenotype
Lymphoid follicles exhibiting the Bcl-2bright+CD10+ B-
cell colonization pattern had GCs that lacked polarization,
displayed a crowded appearance, due to a predominance of
centrocytes, and were surrounded by intact mantle zones.
Rare, residual reactive GC components were nevertheless
noted, including occasional centroblasts (12/13, 92%),
tingible-body macrophages (11/13, 85%), and mitotic figures
(5/13, 38%). The paracortical architecture was unaltered in
all nodal cases (9/9, 100%).
Ten of 13 (77%) primary cases and the recurrent lesion
showed concomitant bright CD10 expression (Table 1),
while the intensity of Bcl-6 (n = 13) and LMO2, OCT2 and
BOB1 (n = 8) was not brighter than adjacent reactive
follicles. The percentage of secondary follicles displaying
colonization by Bcl-2bright+CD10+ B-cells (determined by
Bcl-6, CD10 and Bcl-2 staining) ranged from 18% to 100%
(median 79%); 9/13 (69%) cases demonstrated N50%
follicular involvement (Table 1). The density of follicular
colonization was variable within and between cases;
representative examples of near complete replacement and
mild infiltration of GCs are shown in Fig 1A-C and D-F,
respectively. Of note, the recurrence involving the adenoids(case 3b) displayed a focal mantle zone/perifollicular pattern
of infiltration (Fig 1G, H) despite exhibiting a GC-limited
pattern in the prior lymph node biopsy (case 3a). No
interfollicular Bcl-2bright+CD10+ cellular infiltrate was noted
in any case. Staining for Ki-67 revealed a lower proliferation
index in colonized GCs (range 5%–25%) compared to
uninvolved reactive GCs (40%–50%).
The histologic subtypes of synchronous (n = 6) and
metachronous (n = 3) lymphomas are listed in Table 1. In
brief, all FL were low grade, all DLBCL had centroblastic
morphology, and the two BCL-U exhibited blastoid
morphology. All lymphomas displayed a GC phenotype
(Bcl-6+, CD10+, MUM1−), and the BCL-U had markedly
elevated Ki-67 proliferation indices (70% and 90%). The
Bcl-2bright+CD10+ B-cell follicular colonization pattern was
noted in lymph nodes involved by lymphoma, in adjacent or
regional uninvolved lymph nodes or at mucosal sites at a
distance from a primary intestinal (or non-intestinal)
lymphoma; some cases exhibited this pattern at multiple
sites (Table 1). Representative examples of the different
types of lymphomas and sites of lymphoid follicles
manifesting the Bcl-2bright+CD10+ B-cell colonization pat-
tern are illustrated in Figs. 2-4.
3.3. Cytogenetic analysis
The results of cytogenetic analysis are presented in Table 2.
3.3.1. Follicles exhibiting colonization by
Bcl-2bright+CD10+ B-cells
Karyotype analysis performed in 4 primary cases
exhibiting the Bcl-2bright+CD10+ B-cell follicular coloniza-
tion pattern (cases 3a, 5, 10, and 12) displayed a normal
karyotype (case 5), complex karyotype (cases 3a and 10,
Fig. 5) or a non-clonal karyotype (case 12). Both cases with a
complex karyotype demonstrated t(14;18)(q32;q21); one
exhibited 2 copies of the translocation (case 3a) and the other
an additional translocation t(3;8)(q27;q24) representing a
potential genetic “triple-hit” (case 10). Metaphase FISH
detected IGH/BCL2 rearrangements in 3 of 4 cases (cases 3a,
10, and 12). The adenoid sample (case 3b) revealed a normal
karyotype, and no IGH/BCL2 rearrangement was detected
by FISH (due to lack of lesional tissue).
Interphase FISH analysis, performed on FFPE sections in
9 cases (cases 1, 2, 4, 6, 7, 8, 9, 10, and 11), detected BCL2
rearrangements in 5 (56%) samples (cases 6, 8, 9, 10, and
11), 2 (22%) lacked rearrangements (cases 4 and 7), and 2
(22%) had inconclusive results due to hybridization failure
(cases 1 and 2). FISH for BCL6 and MYC confirmed BCL6
and MYC rearrangements and verified their localization to
the colonized follicles in the lymph node lacking BCL-U
(case 10).
In summary, FISH analysis (metaphase and/or interphase)
confirmed the presence of BCL2 rearrangements within GCs
of colonized follicles in 7 of 10 (70%) informative cases
(cases 3a, 6, 8, 9, 10, 11, 12).
Table 1 Clinical and pathologic characteristics of cases








Site n/total (%) CD10 Sync Meta Site Type Time
to NHL
1 56 F Cholelithiasis Cystic Duct
LN
72/73 (99%) Bright No No N/A N/A NA 0 UNK No None Alive, NED
(61 mo)
2 78 M Skin Lesion Skin 3/17 (18%) Bright No UNK N/A N/A NA UNK UNK ND UNK LTF
3a 60 F Lymphadenopathy,
parotid mass
Cervical LN 75/95 (79%) Bright No* No N/A N/A NA 0 4 ND Rituximab Alive, AWD
(96 mo)
3b Breathing difficulty Adenoids 2/15 (13%) Bright No No** N/A N/A NA NA 4 ND None
4 49 F Thyroid nodule Thyroid 6/20 (20%) Bright No UNK N/A N/A NA UNK 1 ND UNK LTF





9/22 (41%) Bright No No N/A N/A NA 1 1A ND None Alive, NED
(50 mo)
6 65 M Axillary
lymphadenopathy
Axillary LN 9/13 (69%) Bright Yes No Axillary LN Low-grade
FL
NA 0 1A ND None Alive, NED
(18 mo)
7 43 F Pelvic pain Ileum 14/14 (100%) Normal Yes No Ileum Low-grade
FL
NA 0 2A ND Rituximab Alive, NED
(13 mo)
8 59 F Abdominal pain Mesenteric
LN &
Jejunum
65/65 (100%) Bright Yes No Mesenteric mass,
jejunal
involvement
DLBCL NA 1 1A ND R-CHOP
(3 Cycles)
LTF
9 58 F Hematuria,
radiographic
imaging
















11 76 F Pancreatic mass Peripancreatic
LN
20/21 (95%) Normal Yes No Pancreas,
duodenum,
stomach









39/45 (87%) Bright No Yes Paraaortic LN Low-grade
FL





13 58 F Unknown Postauricular
LN












Abbreviations: M, male; F, female; LN, lymph node; BM, bone marrow involvement; NA, not applicable; Sync, synchronous; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-
CEOP, rituximab plus cyclophosphamide, etoposide, vincristine, and prednisone; CODOX-M/IVAC, cyclophosphamide, vincristine, doxorubicin, and methotrexatek/ifosfamide, etoposide and cytarabine; Meta,
metachronous; normal, similar staining intensity as reactive germinal centers; UNK, unknown; ND, not done; LTF, lost to follow-up; NED, no evidence of disease; AWD, alive with disease; DOD, dead of disease; *, FL









Fig. 1 Reactive lymphoid follicles can show variable degrees and patterns of colonization by Bcl-2bright+CD10+ B-cells. A-C, Lymphoid
follicle (case 12) demonstrating complete colonization of GC by centrocytic Bcl-2bright+CD10bright+ B-cells. (A: H&E, 100×; B: CD10, 100×;
C: Bcl-2, 100×). D-F, Follicle (case 12) exhibiting a milder GC infiltrate of centrocytic Bcl-2bright+CD10bright+ B-cells (D: H&E, 100×; E:
CD10, 100×; F: Bcl-2, 100×). G-I, Adenoid biopsy (case 3b) showing a lymphoid follicle with focal mantle-zone and perifollicular infiltrate of
centrocytic Bcl-2bright+CD10bright+ B-cells. (G: H&E, 40×; H: CD10, 40×; I: Bcl-2, 40×).
1332 J. C. Lee et al.3.3.2. Synchronous and metachronous lymphomas
Karyotype analysis performed in 3 of 6 synchronous
lymphomas (cases 7, 8, and 10) detected t(14;18)(q32;q21)
in two cases (cases 7 and 10); one (case 8) was a failure. Case
10 also demonstrated t(3;8)(q27;q24). Metaphase FISH
confirmed BCL2 rearrangements in cases 7 and 10, while
metaphase FISH forMYC and BCL6, performed in the latter,
confirmed the genetic “triple-hit.”
Interphase FISH performed in 4 cases (cases 6, 8, 9, and 11)
detected BCL2 rearrangements in all (100%). Additionally,
interphase FISH performed on a peripheral blood sample from
one patient (case 11) demonstrated BCL2 rearrangement at a
very low frequency (8/1608 cells), despite the inability of flow
cytometry to detect circulating neoplastic cells (data not shown).
Karyotype analysis of the 2 metachronous lymphomas
(cases 12 and 13) revealed t(14;18)(q32;q21) in the FL and
DLBCL occurring in one individual (case 13), but failed in
one (case 12). Metaphase FISH confirmed the presence of
BCL2 rearrangements in all informative cases.3.4. Immunoglobulin heavy chain gene
rearrangement analysis
The results of PCR analysis for IGH gene rearrangement
performed using whole tissue FFPE sections from 11 cases are
listed in Table 2. Clonal products were detected in 5 of 9 (55%)
informative samples only displaying Bcl-2bright+CD10+ B-cell
follicular colonization (cases 3a, 7, 8, 9, and 11). A clonal
relationship between the primary and recurrence, exhibiting
only Bcl-2bright+CD10+ B-cell follicular colonization (case 3),
could not be established due to exhaustion of lesional tissue in
the recurrence sample.
Four of 5 (80%) synchronous lymphomas analyzed
yielded clonal products (cases 7, 8, 9, 11) of a similar size
as the Bcl-2bright+CD10+ B-cell colonized follicles.
PCR performed on the peripheral blood of one patient
(case 11) detected a similar clonal product as the sample
manifesting follicular colonization by Bcl-2bright+CD10+ B-
cells and the synchronous lymphoma.
Fig. 2 A-D, Mesenteric lymph node biopsy (case 8). A, Low magnification showing scattered, small reactive lymphoid follicles and
preserved nodal architecture, B, GC displays predominance of centrocytic cells. C, GCs showing colonization by CD10bright+ B-cells. D, GC
infiltrate exhibits bright Bcl-2 expression (A: H&E, 20×; B: H&E, 400×; C: CD10, 20×; D: Bcl-2, 20×). E-H, Intramucosal lymphoid follicles
demonstrating GC colonization by Bcl-2bright+CD10bright+ B-cells. E, The mantle zone is preserved while the GCs are colonized by centrocytic
cells. F, GC exhibiting dense infiltrate of centrocytic cells. G, GC-colonizing B-cells show bright CD10 expression. H, The GC infiltrates also
show bright Bcl-2 expression (E: H&E, 20×; F: H&E, 400×; G: CD10, 20×; H: Bcl-2, 20×). I-L, Mesenteric DLBCL showing infiltration of
small bowel wall. I, Large neoplastic lymphocytes infiltrating small bowel submucosa with focal extension into mucosa. J, The neoplastic cells
display centroblastic morphology. K, Lymphoma cells lack CD10 expression. L, Lymphoma cells express Bcl-2 (I: H&E, 20×; J: H&E, 400×;
K: CD10, 400×, L: Bcl-2, 400×).
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Fig. 3 A-D, Cervical lymph node showing effaced architecture due to an infiltrate of BCL-U (case 10). E-H, Another lymph node from the
same region showing reactive follicles, with a few exhibiting GC colonization by Bcl-2bright+CD10+ B-cells. A, Diffuse lymph node infiltrate
of neoplastic lymphocytes. B, Lymphocytes are medium to large in size and have blastoid morphology. C, The infiltrating lymphocytes
express CD10. D, The neoplastic lymphocytes also express Bcl-2. E, A neighboring lymph node shows scattered small reactive lymphoid
follicles with preserved mantle zones and intact lymph node architecture. F, Some GCs show dense infiltrates of centrocytic cells. G, Colonized
GCs show similar intensity of CD10 expression as the BCL-U. H, GC-infiltrating cells show bright Bcl-2 expression (A, E: H&E, 20×; B, F:
H&E, 400×; C: CD10, 40×; D: Bcl-2, 40×; G: CD10, 40×; H: Bcl-2, 40×).
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The clinical characteristics, including biopsy indication,
therapy and outcomes, are summarized in Table 1. The 13
study patients comprised 4 males and 9 females (age range
43–78 years, median 58 years). Clinical follow-up ranged
from 7–122 months (median 18 months); 3 patients were lost
to follow-up shortly after biopsy.
Two of 3 patients (cases 1 and 5) lacking biopsy-proven
synchronous or metachronous lymphomas, with follow-up
information, are alive without therapy and have no evidence
of disease to date. Of interest, one patient (case 3), whose
lymph node biopsy exhibited follicular colonization by Bcl-
2bright+CD10+ B-cells and 2 copies of t(14;18) on karyotype
analysis, had multiple, deep-seated enlarged lymph nodes on
imaging (not biopsied) suggesting stage 4 disease (presum-
ably FL). Radiologic remission was achieved with single
agent rituximab; however, adenoidectomy performed 96
months later for difficulty in breathing revealed follicular
hyperplasia and a focal mantle-zone/perifollicular infiltrate
of Bcl-2bright+CD10bright+ B-cells. All overt synchronous
lymphomas and one metachronous lymphoma (case 12) were
observed in the same region as the tissue or organ displaying
Bcl-2bright+CD10+ B-cell colonized follicles. Seven of
8 (87%) lymphomas were associated with N50% follicles
demonstrating colonization by Bcl-2bright+CD10+ B-cells.
All three patients with FL (cases 6, 7, 12, Table 1) are
currently alive, while 3 of 4 patients with follow-up
information who had or developed aggressive lymphomas
died shortly after diagnosis despite immunochemotherapy.
One patient with BCL-U (case 11, Table 1) is alive with
disease after immunochemotherapy.4. Discussion
The entity of FLIS was first described by Cong et al to
represent the finding of intense Bcl-2 expression by CD10+
B-cells infiltrating reactive follicles in lymph nodes with
otherwise preserved architecture [5]. The GCs of these
follicles had a crowded appearance due to a predominance of
centrocytes, often lacking other reactive GC constituents [5].
Montes-Moreno et al, in their series of FLIS, commented on
the intense CD10 co-expression by the Bcl-2bright+ B-cells
[11]. Similar observations were also reported by Jegalian et
al in a recent large series, which revised (and added to) the
original series of Cong et al [10].
Since its original description, different terminology has
been used to describe this peculiar follicular lymphoproli-
feration, ranging from “in-situ localization of follicular
lymphoma” [5,8] to “intrafollicular neoplasia/in situ follic-
ular lymphoma” [11], to “follicular lymphoma in-situ”
[6,9,10]. The term “in situ” has been used in many tumor
systems, mostly epithelial, to denote a tissue localized, and
often the earliest morphologically recognizable, stage inneoplastic evolution, associated with an indolent course.
Since (1) the genesis of t(14;18) is thought to occur in the
bone marrow, (2) often more than one lymphoid follicle
shows colonization by Bcl-2bright+CD10+ B-cells and (3) the
biology of this lymphoproliferation is not well understood at
present, we have used a descriptive, non-committal term for
this immunoarchitectural pattern, ie, follicular colonization
by Bcl-2bright+CD10+ B-cells.
Our series comprised 14 cases, including 13 primary cases
and one recurrence, involving lymph nodes and extranodal
sites, and all except three displayed concomitant bright
CD10 expression. The density of follicular colonization was
variable within and between cases, but the majority of our
cases demonstrated a higher frequency of follicles manifest-
ing the Bcl-2bright+CD10+ B-cell immunoarchitectural pat-
tern compared to prior reports [5,11]. Most publications have
described this pattern only in lymph nodes or in the spleen.
Jegalian et al recently reported FLIS at extranodal sites, one
case each involving the thyroid and jejunum [10]. We
corroborate and extend this observation. In our series, the
small bowel was the most common primary extranodal site
(60%) manifesting this pattern, and isolated cases involving
the thyroid and subcutaneous tissue were noted. We also
document a mantle-zone/perifollicular pattern of infiltration
of the adenoids for the first time.
The frequency of synchronous or metachronous
lymphomas in patients exhibiting follicular colonization
by Bcl-2bright+CD10+ B-cells has been quite variable in
prior reports. In the series of Cong et al, consisting of 25
cases, synchronous FL was diagnosed in 20% involving
another lymph node; 12% subsequently developed FL,
and 8% had other synchronous low-grade non–GC
derived B-cell lymphomas (chronic lymphocytic leuke-
mia/small lymphocytic lymphoma [CLL/SLL] and lym-
phoplasmacytic lymphoma) [5]. Montes-Moreno et al, in
their study of 13 cases, reported synchronous FL in 23%
and other types of synchronous lymphomas, including
classical Hodgkin lymphoma and splenic marginal zone
lymphoma in 31%, while 15% developed subsequent
lymphomas (FL and DLBCL) [11]. In the recent large
series of Jegalian et al, comprising 34 cases, synchronous
FL was detected in 15% (2 Bcl-2+ and 3 Bcl-2− FL),
15% were composite lymphomas with other low-grade
non–GC derived B-cell lymphomas or interfollicular
Hodgkin lymphoma; subsequent FL developed in 5%,
and only 3% developed a DLBCL [10]. Our findings are
similar to those of Montes-Moreno et al, with overt
synchronous lymphomas observed in 46% of our cases,
which were clonally related to samples exhibiting
follicular colonization by Bcl-2bright+CD10+ B-cells in
80% of analyzed cases. An additional lymphoma was
suspected on imaging that wasn't sampled, while 15%
developed subsequent lymphomas. However, in contrast
to previous studies, the majority of synchronous lympho-
mas (67%) in our series represented “high-grade”
lymphomas (DLBCL and BCL-U).
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the Bcl-2bright+ GCs in 1 of 5 (20%) FLIS cases using laser
capture microdissection and in 43% using whole-tissue
sections by PCR analysis [5], while Montes-Moreno et al
detected BCL2 rearrangements in 85% of cases using both
PCR and FISH analysis [11]. Consistent with prior studies, a
high percentage of our informative samples manifesting
follicular colonization (70%) harbored the t(14;18) by
karyotype and/or FISH analysis, and this translocation was
detected in both components, colonized follicles and
synchronous lymphomas, in 83% of cases. We found a
targeted FISH approach, albeit cumbersome, to yield the
highest detection rate.
Two different pathophysiologic hypotheses for the FLIS
pattern were proposed by Cong et al: 1) a phenomenon
related to homing of lymphoma cells to reactive GCs or 2) a
pre-neoplastic entity requiring additional hits for transfor-
mation [5]. Henopp et al, on detecting a 2.3% prevalence of
FLIS in reactive lymph nodes, which is much higher than the
prevalence of FL (1/10 000), suggested that FLIS could
represent an early stage of lymphomagenesis, with the
majority of patients exhibiting this pattern not progressing to
overt lymphoma [9]. Cheung et al shared a similar view,
based on their study of a patient with FLIS lacking evidence
of disease progression by imaging on prolonged follow-up,
but the presence of circulating cells harboring an identical
t(14;18) led them to argue against FLIS being a limited
process [8].
Jegalian et al speculated that FLIS could be the tissue
counterpart of circulating t(14;18) carrying cells, which can
be observed in healthy individuals [10]. The t(14;18) can be
detected by PCR-based methods in reactive lymphoid tissue
(lymph nodes and tonsils) in up to 54% [15] and the
peripheral blood in up to 55% of normal individuals [16].
The frequency of detecting this translocation in circulating
lymphocytes increases with age [16] and in certain disease
states [17–19]. Currently, there is no definitive evidence
linking FLIS to the presence of circulating cells harboring
t(14;18) in healthy individuals. Follicular colonization by
Bcl-2bright+Bcl-6+ B-cells was not seen in the spleen of an
individual who had circulating cells with t(14;18) [20].
Moreover, transgenic mice with deregulated BCL2 expres-
sion, although not the best models to clarify early
histopathologic alterations of human FL, demonstrate florid
follicular hyperplasia in lymphoid organs early in disease
course rather than a pattern resembling FLIS [21,22].
Validation of FLIS as an early pathogenetic stage in FL
evolution will be challenging, requiring not only sequencingFig. 4 BCL-U involving the head of the pancreas (case 11) (A-D)
Bcl-2bright+CD10+ B-cells (E-H). A, A dense infiltrate of BCL-U in the
exhibit blastoid morphology. C, Lymphoma cells express CD10. D,
displaying scattered, small reactive lymphoid follicles with preserved m
cells have centrocytic morphology. G, GC-infiltrating cells express CD
The GC B-cells show bright Bcl-2 expression (A, E: H&E, 20×; B, F
H: Bcl-2, 200×).of IGH genes, but also concurrent genomic analysis of
circulating cells carrying t(14;18), as well as GCs colonized
by Bcl-2bright+CD10+ B-cells in the same individual.
Complicating such analysis is also the recent revelation
that FL progression patterns are complex and not linear as
previously thought [23].
Bonzheim et al provided evidence in support of FLIS
being a precursor to overt FL [6]. They detected the same
IGH gene rearrangement and BCL2 translocations in a
lymph node with FLIS and a synchronous Bcl-2− FL in
another lymph node; however, unlike the FLIS, the Bcl-2−
FL had acquired multiple numerical chromosomal aberra-
tions and a BCL2 mutation [6]. Carbone et al described a
similar case, where Bcl-2− FL and FLIS, observed as
distinct components in the same lymph node, had similar
IGH gene rearrangement products by PCR, but they
suggested that bright Bcl-2 acquisition by FLIS likely
reflected a homing-related phenomenon of FL cells to
reactive GCs [7,24].
The two hypotheses of Cong et al are not necessarily
mutually exclusive [5]. Although, a pre-neoplastic or a
distinct precursor stage of Bcl-2bright+CD10+ B-cells colo-
nizing reactive follicles can neither be proven nor refuted for
many of our cases, unique features of some cases suggest that
follicular colonization by Bcl-2bright+CD10+ B-cells may
represent a peculiar lymphoid tissue homing-related phe-
nomenon of certain lymphomas. Complex cytogenetic
aberrations were detected in two cases. In one instance, a
clonally related aggressive BCL-U involving a neighboring
lymph node harbored an identical abnormality, a rare type of
genetic “triple-hit” comprising t(14;18)(q32;q21) and
t(3;8)(q27;q24), which is associated with adverse clinical
outcomes [25]. In the other case, imaging studies suggested
the presence of systemic, unsampled lymphoma. Variability
in staining intensity of Bcl-2 and CD10 between colonized
follicles and clonally related lymphomas was also evident in
some cases. Hence, besides FL, aggressive lymphomas of
GC origin or phenotype may also traffic to reactive GCs, on
occasion, where microenvironment-specific signals could
modulate the cytologic appearance, proliferative activity and
expression of Bcl-2 and other antigens. Modulation of a
variety of antigens upon GC entry and exit by normal or
neoplastic B-cells is a well described phenomenon [26].
The clinical significance of cases manifesting the Bcl-
2bright+CD10+ B-cell follicular colonization pattern remains
poorly understood at present. Many patients exhibiting this
pattern do not develop overt lymphoma for long periods,
while others have synchronous lymphoma, includingand a peripancreatic lymph node exhibiting GC colonization by
pancreas. B, Neoplastic lymphocytes are intermediate in size and
Lymphoma cells express Bcl-2. E, Peripancreatic lymph node
antle zones and intact lymph node architecture. F, GC-colonizing
10, which is similar in intensity to adjacent reactive follicles. H,
: H&E, 400×; C: CD10, 400×; D: Bcl-2, 400×; G: CD10, 200×;
Table 2 Cytogenetic and molecular findings
Case Bcl-2bright+CD10+ follicles Lymphoma
Karyotype FISH metaphase FISH FFPE IGH
PCR
Sync Meta Karyotype FISH metaphase FISH FFPE IGH
PCR
1 ND NA BCL2 F ND No NA NA NA NA NA








ND C NA NA NA NA NA
3b NA Bcl-2bright+
CD10+ B-cellsb
F F F PC
4 ND NA BCL2 NR F No NA NA NA NA NA
5 46,XY [20] IGH/BCL2 NR ND PC No No NA NA NA NA




NA ND NA IGH/BCL2 R,
BCL6 NR
ND








8 ND NA BCL2 R Ca DLBCL NA F ND BCL2 R Ca






BCL6 R, MYC R
BCL2 R, BCL6 R,
MYC R




BCL6 R, MYC R
ND PC
11 ND NA IGH/BCL2 R,
BCL6 NR






IGH/BCL2 R ND PC No Low-grade FL F IGH/BCL2 F NA ND
13 ND ND ND PC No A: Low-grade
FL
A: t(14;18)(q32;q21),+7 A: IGH/BCL2 R,
BCL6 NR
NA A: C








Abbreviations: Sync, synchronous lymphoma, Meta, metachronous lymphoma, NA, not applicable; ND, not done; F, failure; R, rearranged; NR, not rearranged; C, clonal; PC, polyclonal.







Fig. 5 A, G-band karyotype obtained from a lymph node displaying GC colonization by Bcl-2bright+CD10+ B-cells (case 10) that was
adjacent to a lymph node involved by BCL-U [black arrows indicate t(14;18)(q32;q21), and white arrows demonstrate t(3;8)(q27;q24)]. B,
Metaphase FISH using IGH/BCL2 dual-color fusion probes [yellow arrow indicates IGH/BCL2 fusion signal; green arrow shows intact IGH
locus; red arrow shows normal copy of BCL2]. C, Metaphase FISH using MYC break-apart probes [yellow arrow indicates intact MYC, green
arrow shows 3′MYC on der(3), and red arrow shows 5′MYC on der(8)]. D, Interphase FISH targeting colonized follicles (FFPE sections) with
BCL2 break-apart probes [yellow arrow indicates intact BCL2, green arrow shows 3′ BCL2, and red arrow shows 5′ BCL2 confirming BCL2
rearrangement]. E, Interphase FISH targeting colonized follicles (FFPE sections) with MYC break-apart probes [yellow arrow indicates intact
MYC, green arrow shows 3′ MYC, and red arrow shows 5′ MYC confirming MYC rearrangement]. F, G-band karyotype of a lymph node
showing GC colonization by Bcl-2bright+CD10bright+ B-cells without histologic or phenotypic evidence of lymphoma (case 3a), but imaging
studies suggested stage 4 disease [black and white arrows show multiple copies of t(14;18)(q32;q21)]. G, Interphase FISH using IGH/BCL2
probes showed 2 copies and rare cells displayed multiple copies of rearranged IGH/BCL2 [yellow arrows – IGH/BCL2 fusions].
1339Follicular colonization by Bcl-2bright+CD10+ B-cellsaggressive variants, or they may subsequently develop
lymphoma. Jegalian et al proposed histopathologic and
phenotypic criteria to distinguish more indolent prolifera-
tions from partial lymph node involvement by FL (PFL) [10].
Using a combination of features, including subtle alterations
in follicle architecture, extent of GC infiltration, cytology of
infiltrating cells, presence of interfollicular infiltrate, and
variability in Bcl-2 and CD10 intensity, the authors
reclassified 9 of 25 (36%) previously reported FLIS
cases [5] as having PFL, of which 8 were found to have
concurrent or subsequent FL [10]. A correct diagnosis of
FLIS was suggested to portend a low risk of developing
lymphoma, however, a significant fraction of untreatedindividuals with PFL (47%) also lacked evidence of disease
on follow-up [10]. Our cases lacked morphologic criteria of
PFL; however, 50% of cases associated with concurrent
lymphomas did not express bright CD10. Additionally, we
observed a high frequency of follicles manifesting the
colonization pattern in samples from virtually all patients
with synchronous or metachronous lymphomas. Molecular
or cytogenetic analysis might be helpful in predicting
concomitant overt or aggressive lymphomas elsewhere
when biopsies only exhibit the follicular colonization
pattern, as exemplified in this study. Given the small number
of cases and relatively short follow-up duration, future
studies are warranted to confirm our observations. In the
1340 J. C. Lee et al.absence of definitive pathologic and molecular features
enabling risk stratification at present, we support the
recommendation of Carbone and Santoro, who advocate
full staging workup to rule out coexistent lymphoma [27].
Scheduled clinical follow-up evaluation might also be
prudent to detect disease progression or transformation, as
is the case for individuals with FL.
In summary, we present a series of cases exhibiting a
pattern of follicular colonization by Bcl-2bright+CD10+B-
cells in architecturally intact lymph nodes and at extranodal
sites. We describe a higher incidence of synchronous
lymphomas, especially high-grade variants than prior re-
ports. Some of the unique characteristics of our cases suggest
that this distinct immunoarchitectural pattern might reflect a
phenomenon associated with homing of neoplastic B-cells to
reactive follicles, at times representing evolved clones, rather
than indicate a particular stage in FL development.References
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